NBGI Private Equity has acquired Stiplastics for an undisclosed sum.
Stiplastics is a manufacturer of injection-moulded plastic dosing, packaging solutions and medical devices for the pharmaceutical industry including pillboxes, medication blister packs, and “tamper proof” systems.
The company employs around 70 staff and operates production facilities in Beauvoir en Royans, France.
NBGI will support the company’s existing management team, which has ambitious plans to almost double revenues in the next five years, from EUR12.5m in 2012 to EUR23m in 2017. The strategy is to expand Stiplastics’ range of products and to leverage its reputation and relationships around the world. Over 50 per cent of the company’s sales are generated outside of France and its local partners have already expressed strong interest in distributing the new products that are currently under development.
Stiplastics is the third investment made from NBGI Private Equity France Fund I.
Laurent Allégot, investment director, NBGI Private Equity, says: “We are delighted to back Stiplastics, and are looking forward to working with its experienced management team in capitalising on its strong international exposure and major new projects under development. The company operates in a fragmented market and we also see it as an ideal platform from which to benefit from future consolidation.”
Jerome Empereur, chief executive of Stiplastics, says: “We have ambitious plans for Stiplastics, and NBGI’s deep knowledge of the sector in which we operate makes it the right partner to support us through the various stages of growth we envisage over the next few years.”
Advisers for NBGI on the transaction included HPML (legal), Audexo (financial due diligence) and PwC (commercial due diligence).
